Product Name
FOXE3, siRNA
Full Product Name
FOXE3 siRNA (Human)
Product Synonym Names
FKHL12; FREAC8; Forkhead box protein E3; Forkhead-related protein FKHL12; Forkhead-related transcription factor 8; FREAC-8
Product Gene Name
FOXE3 sirna
[Similar Products]
Research Use Only
For Research Use Only. Not for use in diagnostic procedures.
3D Structure
ModBase 3D Structure for Q13461
Specificity
FOXE3 siRNA (Human) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
Purity/Purification
> 97%
Form/Format
Lyophilized powder
Quality Control
Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
Directions for Use
We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
Components
We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of human FOXE3 gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
Preparation and Storage
Shipped at 4 degree C. Store at -20 degree C for one year.
Negative Control
siRNA Negative Control (Catalog# MBS8241404) is a non-targeting 21 nt siRNA recommended as a negative control for experiments using targeted siRNA transfection.
Other Notes
Small volumes of FOXE3 sirna vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.
Related Product Information for
FOXE3 sirna
siRNA to inhibit FOXE3 expression using RNA interference
Applications Tested/Suitable for FOXE3 sirna
RNA Interference (RNAi)
NCBI/Uniprot data below describe general gene information for FOXE3. It may not necessarily be applicable to this product.
NCBI Accession #
NP_036318.1
[Other Products]
NCBI GenBank Nucleotide #
NM_012186.2
[Other Products]
UniProt Primary Accession #
Q13461
[Other Products]
UniProt Secondary Accession #
Q5SVY9; Q9NQV9[Other Products]
UniProt Related Accession #
Q13461[Other Products]
Molecular Weight
33,234 Da
NCBI Official Full Name
forkhead box protein E3
NCBI Official Synonym Full Names
forkhead box E3
NCBI Official Symbol
FOXE3 [Similar Products]
NCBI Official Synonym Symbols
FKHL12; FREAC8
[Similar Products]
NCBI Protein Information
forkhead box protein E3
UniProt Protein Name
Forkhead box protein E3
UniProt Synonym Protein Names
Forkhead-related protein FKHL12; Forkhead-related transcription factor 8; FREAC-8
Protein Family
Forkhead box protein
UniProt Gene Name
FOXE3 [Similar Products]
UniProt Synonym Gene Names
FKHL12; FREAC8; FREAC-8 [Similar Products]
UniProt Entry Name
FOXE3_HUMAN
NCBI Summary for FOXE3
This intronless gene belongs to the forkhead family of transcription factors, which is characterized by a distinct forkhead domain. The protein encoded functions as a lens-specific transcription factor and plays an important role in vertebrate lens formation. Mutations in this gene are associated with anterior segment mesenchymal dysgenesis and congenital primary aphakia. [provided by RefSeq, Dec 2009]
UniProt Comments for FOXE3
FOXE3: Defects in FOXE3 are a cause of anterior segment mesenchymal dysgenesis (ASMD); also known as anterior segment ocular dysgenesis (ASOD). ASMD consists of a range of developmental defects in structures at the front of the eye, resulting from abnormal migration or differentiation of the neural crest derived mesenchymal cells that give rise to the cornea, iris, and other components of the anterior chamber during eye development. Mature anterior segment anomalies are associated with an increased risk of glaucoma and corneal opacity. Conditions falling within the phenotypic spectrum include aniridia, posterior embryotoxon, Axenfeld anomaly, Reiger anomaly/syndrome, Peters anomaly, and iridogoniodysgenesis. Defects in FOXE3 are a cause of congenital primary aphakia (CPA). Aphakia is a rare congenital eye disorder in which the lens is missing. It has been histologically subdivided into primary and secondary forms, in accordance with the severity of defects of the ocular tissues, whose development requires the initial presence of a lens. CPA results from an early developmental arrest, around the 4th-5th week of gestation in humans, that prevents the formation of any lens structure and leads to severe secondary ocular defects, including a complete aplasia of the anterior segment of the eye. In contrast, in secondary aphakic eyes, lens induction has occurred, and the lens vesicle has developed to some degree but finally has progressively resorbed perinatally, leading, therefore, to less-severe ocular defects.
Protein type: DNA-binding
Chromosomal Location of Human Ortholog: 1p32
Cellular Component: transcription factor complex; nucleus
Molecular Function: sequence-specific DNA binding; transcription factor activity
Biological Process: transcription from RNA polymerase II promoter; regulation of transcription from RNA polymerase II promoter; camera-type eye development; cell development; positive regulation of epithelial cell proliferation
Disease: Anterior Segment Mesenchymal Dysgenesis; Aphakia, Congenital Primary
Research Articles on FOXE3
1. Our results indicate that the FOXE3 p.Val201Met allele is associated with eye defects (OR = 3.5), suggesting its involvement as an ocular malformation risk factor.
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.
It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
